{"id":"https://openalex.org/W2000599126","doi":"https://doi.org/10.1016/j.bmc.2012.04.008","title":"Synthesis and evaluation of \u03b3-lactam analogs of PGE2 as EP4 and EP2/EP4 agonists","display_name":"Synthesis and evaluation of \u03b3-lactam analogs of PGE2 as EP4 and EP2/EP4 agonists","alternate_titles":[],"publication_year":2012,"publication_date":"2012-04-12","ids":{"openalex":"https://openalex.org/W2000599126","doi":"https://doi.org/10.1016/j.bmc.2012.04.008","mag":"2000599126","pmid":"https://pubmed.ncbi.nlm.nih.gov/22546206"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmc.2012.04.008","doi":"https://doi.org/10.1016/j.bmc.2012.04.008","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmc.2012.04.008","pdf_url":null,"source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic &amp; Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000599126"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009660582","display_name":"Tohru Kambe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Tohru Kambe","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan. kanbe@ono.co.jp","Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan. kanbe@ono.co.jp","institution_ids":["https://openalex.org/I4210112155"]},{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101981160","display_name":"Toru Maruyama","orcid":"https://orcid.org/0000-0001-6543-4377","observed_orcids":["https://orcid.org/0000-0001-6543-4377"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toru Maruyama","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111692638","display_name":"Yoshihiko Nakai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshihiko Nakai","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017210229","display_name":"Hiroji Oida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroji Oida","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077691716","display_name":"Takayuki Maruyama","orcid":"https://orcid.org/0000-0003-2205-8310","observed_orcids":["https://orcid.org/0000-0003-2205-8310"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takayuki Maruyama","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012605265","display_name":"Nobutaka Abe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Nobutaka Abe","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024947648","display_name":"Akio Nishiura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akio Nishiura","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044537872","display_name":"Hisao Nakai","orcid":"https://orcid.org/0000-0001-9633-0255","observed_orcids":["https://orcid.org/0000-0001-9633-0255"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisao Nakai","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110809551","display_name":"Masaaki Toda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masaaki Toda","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5009660582"],"corresponding_institution_ids":["https://openalex.org/I4210112155"],"apc_list":{"value":3960,"currency":"USD","value_usd":3960},"apc_paid":null,"fwci":1.57,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.79782883,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"20","issue":"11","first_page":"3502","last_page":"3522"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.008999999612569809,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prostaglandin-e2-analogue","display_name":"prostaglandin E2 analogue","score":0.921999990940094},{"id":"https://openalex.org/keywords/ep4-receptor-agonist","display_name":"EP4 receptor agonist","score":0.906000018119812},{"id":"https://openalex.org/keywords/sustained-release","display_name":"sustained drug release","score":0.8130000233650208},{"id":"https://openalex.org/keywords/topical-drug-delivery","display_name":"topical drug delivery","score":0.8169999718666077},{"id":"https://openalex.org/keywords/fracture-healing","display_name":"fracture healing","score":0.9750000238418579},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.9150000214576721},{"id":"https://openalex.org/keywords/receptor-subtype-selectivity","display_name":"receptor subtype selectivity","score":0.7210000157356262}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8839011192321777},{"id":"https://openalex.org/C2776131168","wikidata":"https://www.wikidata.org/wiki/Q251124","display_name":"Lactam","level":2,"score":0.7621451616287231},{"id":"https://openalex.org/C2776568683","wikidata":"https://www.wikidata.org/wiki/Q23005640","display_name":"Moiety","level":2,"score":0.7070310711860657},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6400096416473389},{"id":"https://openalex.org/C2779074116","wikidata":"https://www.wikidata.org/wiki/Q134856","display_name":"Carboxylic acid","level":2,"score":0.49196574091911316},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4906093180179596},{"id":"https://openalex.org/C178592051","wikidata":"https://www.wikidata.org/wiki/Q28208812","display_name":"Prostaglandin E2 receptor","level":4,"score":0.48108622431755066},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4442695081233978},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.43141013383865356},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4106491804122925},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3067800998687744},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.30041199922561646},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000287","descriptor_name":"Administration, Topical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D006224","descriptor_name":"Cricetinae","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006339","descriptor_name":"Heart Rate","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D007769","descriptor_name":"Lactams","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007769","descriptor_name":"Lactams","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D007769","descriptor_name":"Lactams","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008863","descriptor_name":"Microspheres","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011098","descriptor_name":"Polyglactin 910","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011098","descriptor_name":"Polyglactin 910","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011459","descriptor_name":"Prostaglandins E, Synthetic","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D011459","descriptor_name":"Prostaglandins E, Synthetic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015232","descriptor_name":"Dinoprostone","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016466","descriptor_name":"CHO Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017102","descriptor_name":"Fracture Healing","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053778","descriptor_name":"Thiazolidines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D058307","descriptor_name":"Receptors, Prostaglandin E, EP2 Subtype","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D058309","descriptor_name":"Receptors, Prostaglandin E, EP4 Subtype","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.bmc.2012.04.008","doi":"https://doi.org/10.1016/j.bmc.2012.04.008","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmc.2012.04.008","pdf_url":null,"source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic &amp; Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:22546206","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22546206","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9476000070571899,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1982453148","https://openalex.org/W1982793567","https://openalex.org/W2006036221","https://openalex.org/W2010901408","https://openalex.org/W2011908788","https://openalex.org/W2027893787","https://openalex.org/W2049449641","https://openalex.org/W2050304406","https://openalex.org/W2054930916","https://openalex.org/W2056879221","https://openalex.org/W2083071121","https://openalex.org/W2084615605","https://openalex.org/W2095774478","https://openalex.org/W2108783581","https://openalex.org/W2121612337","https://openalex.org/W2122427056"],"related_works":["https://openalex.org/W2027893787","https://openalex.org/W2056879221","https://openalex.org/W1982453148","https://openalex.org/W2177323728","https://openalex.org/W2011908788","https://openalex.org/W1982793567","https://openalex.org/W2149886203","https://openalex.org/W2006036221","https://openalex.org/W2022793771","https://openalex.org/W2050304406"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2000599126","counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
